CARY, NC--(Marketwire - November 07, 2012) - Cornerstone Therapeutics Inc.
), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty markets, announced today the appointment of Alastair McEwan as Chief Financial Officer (CFO) effective November 6, 2012.
Mr. McEwan is a pharmaceutical industry executive with more than 30 years experience. He has been instrumental in numerous strategic initiatives, notably in the healthcare sector, including public and private mergers and acquisitions, divestments and capital restructuring, and organizational restructuring and combinations. He has served in many senior management positions and on executive boards and Boards of Directors including those of Averion International and Inveresk Research. He is a previous chairman of the Cornerstone Board of Directors.
"We are delighted to have Alastair join our executive management team as CFO," said Craig A. Collard, Cornerstone's Chief Executive Officer. "This is an exciting time at Cornerstone as we continue to grow through the acquisition of companies and products that fit within our core focus areas in the hospital market. Alastair shares our strategic vision for the Company and will play a critical role as we work to further establish our presence and reputation as a leader in the hospital and related specialty markets."
Mr. McEwan earned his Bachelor of Commerce degree from the University of Edinburgh, and is a chartered accountant under the Institute of Chartered Accountants of Scotland.
About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty markets. Key elements of the Company's strategy are to focus its commercial and development efforts in the hospital and related specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed and/or registration-stage products, and late-stage development products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more information, visit www.crtx.com.